Monday November 30, 2020 from 09:00 to 09:30
Presenter
Overview
Download the Presentation as a PDF
Esketamine (Spravato) was approved by Health Canada for treatment resistant depression in 2020. It is the first medication in its class available for this indication. This presentation will review the potenital role of esketamine in the treatment of major depressive disorder.
Objectives
As a result of attending this session, participants will be able to:
- Know the definition of treatment resistant depression
- Know the risks and benefits of esketamine
- Understand barriers and challenges involved in using esketamine in clincial practice
Recommended Reading Websites
Lectures by Daniel Zigman
| When | Session | Talk Title | Room |
|---|---|---|---|
|
Mon-30 08:30 - 10:35 |
Plenary - 1 | Esketamine: A game changer in depression treatment? | |
|
Mon-30 11:00 - 12:00 |
What really works in treatment-resistant depression? - Daniel Zigman | What really works in treatment-resistant depression? |